First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC By Ogkologos - February 17, 2025 918 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR News digest – HPV vaccine, 1 million breast screenings missed and... October 3, 2020 Marc Cuban’s Cost Plus Drug Company: A Potential Gold Mine for... January 26, 2022 6-Year-Old Uses Money From Lemonade Stand To Take Mom Out On... August 6, 2019 Sacituzumab Govitecan Prolongs Survival in Relapsed or Refractory Metastatic Triple Negative... April 27, 2021 Load more HOT NEWS The Nobel Prize winner helping us treat children’s cancers FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab
